Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082888 · ClinicalTrials.gov registry record · Phase 2
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT00082888: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00082888 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00082888, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
This phase II trial studies how well tipifarnib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Tipifarnib may be an effective treatment for non-Hodgkin's lymphoma.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2004-03-24 |
| Est. Completion | 2017-07-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082888
The ClinicalTrials.gov registry entry for NCT00082888 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00082888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082888 about?
NCT00082888 is a clinical study titled "Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma". This phase II trial studies how well tipifarnib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Tipifarnib may be an effective treatment for non-Hodgkin's lymphoma.
What is the current status of trial NCT00082888?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2004-03-24. Estimated completion is 2017-07-05.
What interventions are being tested in trial NCT00082888?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00082888?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.